Cite
Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel.
MLA
Zinzani, Pier Luigi, et al. “Unmet Clinical Needs in the Use of Zanubrutinib in Malignant Lymphomas (Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Mantle Cell Lymphoma): A Consensus-Based Position Paper from an Ad Hoc Expert Panel.” Hematological Oncology, vol. 41, no. 5, Dec. 2023, pp. 795–808. EBSCOhost, https://doi.org/10.1002/hon.3172.
APA
Zinzani, P. L., Mauro, F. R., Tedeschi, A., Varettoni, M., Zaja, F., & Barosi, G. (2023). Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel. Hematological Oncology, 41(5), 795–808. https://doi.org/10.1002/hon.3172
Chicago
Zinzani, Pier Luigi, Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, and Giovanni Barosi. 2023. “Unmet Clinical Needs in the Use of Zanubrutinib in Malignant Lymphomas (Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Mantle Cell Lymphoma): A Consensus-Based Position Paper from an Ad Hoc Expert Panel.” Hematological Oncology 41 (5): 795–808. doi:10.1002/hon.3172.